[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590265":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":28,"locations":38,"responsibleParty":56,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":10,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients undergo PCD-CT on study.",[13],"Procedure: PCD-CT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","PCD-CT","Participants undergo PCD-CT scan on study",[9],[21,22],"contrast-enhanced photon-counting detector CT","contrast-enhanced photon-counting detector computed tomography",[24],{"name":25,"affiliation":26,"role":27},"Joel G. Fletcher, MD","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[29,34],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",{"name":35,"role":31,"phone":36,"phoneExt":10,"email":37},"Boleyn Andrist","507-538-7752","andrist.boleyn@mayo.edu",[39],{"facility":26,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-92.4699,44.02163,{"lat":50,"lon":49},[53,54,55],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},{"name":35,"role":31,"phone":36,"phoneExt":10,"email":37},{"name":25,"role":27,"phone":10,"phoneExt":10,"email":10},{"type":57,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100590265","contrast-enhanced-photon-counting-detector-ct-pcd-ct-for-the-local-staging-of-rectal-cancer-100590265",false,"NCT06965166","Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer","Pilot Prospective Study of Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer","Inclusion Criteria:\n\n* Adult patients 18 to 99 years of age\n* Patients with proven rectal cancer clinically referred for staging pelvic MRI and contrast-enhanced CT of the abdomen and pelvis (for evaluation of liver and peritoneal disease)\n* Endoscopic or imaging report that tumor is 2 cm or larger\n* Patients who are able and willing to sign the informed consent\n* Negative pregnancy test if subject is of child-bearing age (females of child-bearing potential will be screened for pregnancy using a urine pregnancy test, which will be administered by the unit study coordinator at no cost to the patient)\n\nExclusion Criteria:\n\n* Minors less than 18 years old\n* Patient unable to provide written informed consent\n* Pregnancy\n* Estimated Glomerular Filtration Rate (eGFR) ≤ 60\n* History of prior moderate or severe contrast reaction including unresponsiveness, severe respiratory distress, convulsions, arrhythmia, cardiopulmonary distress, progressive angioedema, laryngeal edema, dyspnea, bronchospasm, symptomatic tachycardia, symptomatic bradycardia, hypotension, hypertensive crisis\n* Any history of premedication prior to iodinated contrast\n* Bilateral hip replacement\u002Fprosthesis\n* Patients that consent to participation but do not undergo their clinically indicated MRI scanning for any reason (e.g., bad IV, infiltration, reaction, change in indication)","ALL","18 Years","99 Years",{"count":69,"type":70},200,"ESTIMATED","OBSERVATIONAL","This study evaluates whether images taken using a photon counting detector CT scanner (PCD-CT) can determine the growth of rectal cancer as well as, or better than, MRI for the management of patients with rectal cancer.",[74],"Rectal Carcinoma","2026-04-17",{"date":77,"type":78},"2026-04-22","ACTUAL",{"date":80,"type":78},"2024-10-07",{"date":82,"type":70},"2026-12-31",{"name":5,"class":6},1]